![]() |
|
|
-Glutamyl Hydrolase from Human Sarcoma HT-1080 Cells:
Characterization and Inhibition by Glutamine Antagonists
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| |
Summary |
|---|
|
|
|---|
Elevated
-glutamyl hydrolase (GGH) activity as a contributing factor
in mechanisms of acquired and intrinsic antifolate resistance has been
reported for several cultured cell lines. Despite this, little is known
about this enzyme, especially the human species. Using the human
HT-1080 sarcoma line, we observed the secretion of GGH activity into
media during culture (a phenomenon that could be markedly stimulated by
exposure to NH4Cl) and an acidic pH optimum for in
vitro catalytic activity of the enzyme. These properties are
consistent with a lysosomal location for the enzyme. Unlike rodent GGH,
preparations of HT-1080 enzyme (purified
2000-fold) displayed
exopeptidase activity in cleaving successive end-terminal
-glutamyl
groups from poly-L-
-glutamyl derivatives of folate, methotrexate (MTX), and para-aminobenzoic acid
substrates and a marked preference for long-chain polyglutamates
(Km values for glu4
versus glu1 derivatives were 17- and 15-fold lower for
folate and MTX versions, respectively). Using an in
vitro assay screen, several glutamine antagonists [i.e.,
6-diazo-5-oxo-norleucine (DON), acivicin, and azaserine] were
identified as human GGH inhibitors, with DON being the most potent and
displaying time-dependent inhibition. In cell culture experiments,
simultaneous exposure of DON (10 µM) and
[3H]MTX for 24 hr resulted in modest elevations of the
long-chain
-glutamyl derivatives of the antifolate for HT-1080 and
another human sarcoma line. These compounds may serve as useful lead
compounds in the development of specific GGH inhibitors for use in
examining the relationship between GGH activity and antifolate action
and may potentially be used in clinical combination with antifolates that require polyglutamylation for effective cellular retention.
| |
Introduction |
|---|
|
|
|---|
Over the past decade, the
importance of the role of polyglutamylation in the cellular retention
of both folic acid derivatives and antifolates has become more widely
recognized. As polyglutamyl derivatives, these metabolites are usually
the preferred substrates for folate-dependent enzymes, are far less
permeable to the plasma membrane, and may also determine subcellular
localization (1-3). Prolonged retention of one antifolate compound
commonly used as an antineoplastic agent, MTX
(4-NH2-10-CH3-Pteglu1),
results in more effective inhibition of dihydrofolate reductase and is
thought to provide the basis for tumor selectivity (1). The
polyglutamylation process is dependent on at least two cellular enzyme
activities: folylpolyglutamate synthetase (EC 6.3.2.17) which adds
successive glutamate groups to the
-glutamyl side chain of
folates/antifolates, and GGH (EC 3.4.22.12), which removes (hydrolyzes)
the polyglutamate side chain via either an endopeptidase or
exopeptidase activity. In many cases, the second enzyme is sequestered
into lysosomal bodies, and the rate of transport of folylpolyglutamate
into and out of this organelle may also regulate the degree of
polyglutamylation (4).
A considerable amount of information on folylpolyglutamate synthetase has been elucidated, including its catalytic properties (2, 5), and after isolation and sequencing of the human cDNA (6), work has progressed to recombinantly express the enzyme and determine features of transcriptional control (7). By contrast, relatively little is known about GGH, although the cDNA sequence for the rat enzyme was recently reported (8), and some information on the properties of this enzyme from various species is known. At the enzymological level, available information and its relevance to human GGH are confused by the fact that enzyme content and specificities (endopeptidase or exopeptidase activity) not only vary among species but also cell and tissue type (2, 9-11). It seems that this group of enzymes falls into one of two classes; one that is lysosomal in origin (10, 12-15), with an acid pH optimum, and another, smaller group that has a neutral or alkaline pH optimum. It is the enzyme from the former group that seems to be of importance in regulating folate and antifolate polyglutamate chain lengths (1, 2, 16, 17). Of this class, the bovine hepatic enzyme and the human intracellular jejunal enzyme have been studied most extensively. Bovine enzyme was purified to (apparent) homogeneity, confirmed to be a glycoprotein with highly reactive sulfydryl groups, and displayed an apparent molecular mass of 108 kDa (12). Although the partially pure human intracellular jejunal enzyme displayed a much lower apparent molecular mass on gel filtration (75 kDa), many of its other properties were similar to those of the bovine enzyme, including the ability to cleave both terminal and internal linkages of folylpolyglutamates (10). This activity preference differs from the strict exopeptidase action found for GGH from human jejunal brush border cells, which probably plays a role in the digestion of dietary folate (14), and very early work with human liver (lysosomal) GGH (18).
Other studies from the laboratories of Galivan and Sirotnak have focused on rodent forms of GGH and, in particular, the secreted forms harvested from cultured cell lines (11, 19). Interestingly, the enzymological properties of the secreted GGH are not different from the cellular (lysosomal) form. Purified GGH secreted from rat H35 hepatoma cells was shown to have extensive carbohydrate modification, and the deduced amino acid sequence from the cDNA sequence indicates a molecular mass of 33.4 kDa for the peptide component of this enzyme species (8).
Clearly more information on the human enzyme or enzymes is necessary to better define the role of GGH in the regulation of intracellular polyglutamate levels (and therefore cellular retention) of folates and antifolates in human cells. Here, we report the partial purification and characterization of GGH from the human fibrosarcoma cell line HT-1080. Purified GGH preparations were also used to test a broad range of potential inhibitor compounds and certain glutamine antagonists demonstrated inhibitory activity. One of these agents, DON, was found to enhance the cellular retention and cytotoxicity of MTX.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Polyglutamylated derivatives of pteroyl (Pte),
4-NH2-10-CH3-Pte, and pAB
poly-
-L-glutamates were purchased from Dr. B. Schirks Laboratories (Jona, Switzerland). The only exception to this was MTX,
which was from Lederle Laboratories (Pearle River, NY).
[3H]MTX (20 Ci/mmol) was purchased from Moravek
Biochemicals (Brea, CA). Reagents for enzymatic assays of
-hexosaminidase and dihydrofolate reductase were from Sigma Chemical
(St. Louis, MO) or as described (20). Affinity media Reactive Green 5, organomercurial agarose, gel filtration molecular mass standards, and
reagents for cell cytotoxicity measurement were also from Sigma.
Sephacryl S-200 was from Pharmacia (Piscataway, NJ). Several compounds
used in the inhibition screen were kindly donated:
2-mercaptomethylglutaric acid was from Dr. T. I. Kalman (State
University of New York, Buffalo, NY), ICI 198583-
-D-glu
was from Dr. A. L. Jackman (Institute of Cancer Research, Surrey, UK).
All other chemicals were of the highest purity available.
Cell culture and preparation of extracts. Various cancer cell lines, including the soft tissue sarcoma line HT-1080, were obtained from the American Type Culture Collection (Rockville, MD) and cultured in RPMI-1640 containing 2 mM glutamine, 10% fetal bovine serum, and antibiotics. The cytotoxic effect of various agents on the HT-1080 line, using variable concentrations and exposure times, was measured by cell counting or the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide assay (21).
Extracts of HT-1080 cells for enzyme purification were prepared from mid-log growth cultures. After trypsinization and extensive washing with phosphate-buffered saline, cell extract was prepared by sonification and centrifugation steps as previously described (20).Activity assays. GGH activity was measured at 37°, pH 4.5, using 50 µM 4-NH2-10-CH3-Pteglu5 as substrate (unless otherwise stated) and standard assay buffer consisting of the MTEN buffer system (22) with 1 mM ZnCl2 and 2 mM DTT. Portions of the assay mix were sampled at various time points, placed in a boiling water bath for 5 min, and then centrifuged at 14,000 × g. Supernatants were used directly in HPLC analysis to resolve and quantify products as previously described (11). During the course of this work, a capillary electrophoresis procedure was developed for use in quantifying substrate and reaction products of GGH assays (23) and used primarily in inhibitor screening experiments. GGH activity was calculated from the percentage of substrate degraded per unit time (23). One unit is defined as the amount required to convert 1 µmol of substrate/min. Specific activity values (units/mg) were calculated from assay time points where < 20% of substrate was consumed.
-Hexosaminidase activity was measured at pH 4.6 using the substrate
p-nitrophenyl-N-acetyl-
-D-glucosaminidine
as previously described (4, 24). The dihydrofolate reductase and total protein assay protocols have been previously described (20).
Secretion of GGH in cultured HT-1080.
Seeded HT-1080 cells
were grown to early log phase; then, a portion of medium was taken and
snap-frozen in liquid N2. The remaining culture
was spiked with 10 mM NH4Cl, and additional samples of media were taken at days 1, 2, and 5. Medium for a duplicate
flask of cells (without added NH4Cl) was also sampled at
these times. Total protein and enzymatic activities for GGH,
-hexosaminidase, and dihydrofolate reductase were measured in all
samples. The background activities contributed from media alone (close
to negligible) was subtracted from all measurements.
Purification of GGH from HT-1080. Three to 4 ml of clarified crude HT-1080 lysate was dialyzed against buffer A (25 mM Tris·HCl, pH 7.5) and then applied to a 6-ml column of Reactive Green 5 gel previously equilibrated with identical buffer. Throughout the run, flow rate was maintained at 0.8 ml/min, eluate A280 was continuously monitored, and 3-ml fraction volumes were collected. NaCl solutions prepared in buffer A were used to desorb enzyme, and approaches were used in different runs: either (a) a single linear gradient of 0-1.5 M NaCl (100 ml total volume) or (b) multiple step gradients and washing phases. In the second approach, two linear gradients were used (40 ml total volume each) with an intervening wash step of salt strength equivalent to the maximum achieved in the first gradient.
Fractions containing activity from the previous step were pooled, concentrated on YM30 membranes (30 units of Centriprep; Amicon, Beverly, MA), and then dialyzed against buffer B (50 mM Tris·HCl, pH 7.2). Material was then applied (at a flow rate of 0.22 ml/min) to a 1.5-ml gel-bed volume column of organomercurial agarose previously equilibrated with buffer B. After extensive washing (~30 ml), GGH was described with buffer B containing 10 mM DTT. GGH active fractions were pooled and concentrated as before. Gel filtration on Sephacryl S-200 was performed using various preparations of partially pure GGH in the presence or absence of thiols. Optimal results for further purification of organomercurial agarose-purified material was obtained by direct application of active fractions without prior dialysis. In these instances, a column of 1.5 cm (i.d.) × 60 cm (height) was used and running buffer consisted of 20 mM Tris·HCl, pH 7.0, 10 mM NaCl, 2 mM
-mercaptoethanol, and 1 mM DTT.
Characterization of GGH.
Properties of GGH were investigated
using preparations of purity of >3 units/mg (i.e., purified
1500-fold from crude extract); this included experiments examining
the effect of anions, detergents, and urea on GGH activity. The S-200
column and conditions used for estimation of native molecular mass of
GGH was the same as that for purification as described above and in the
figure legend. Isoelectric focusing was performed using a Hoefer gel
unit (GT 1) and operated, essentially, under conditions recommended by the manufacturer (Hoefer Scientific Instruments, San Francisco, CA).
Substrate kinetic analysis. Enzyme was incubated in standard GGH assay buffer (37°) with the different substrates at concentrations (final) of 0.2-250 µM. Incubation times varied from 6.5 min (for 0.2 µM) to 150 min (for >100 µM). Reactions were stopped by boiling, and polyglutamate reaction products were resolved and quantified as described above. Kinetic parameters were subsequently determined by fitting to data the Michaelis-Menten equation using nonlinear, least-squares regression analysis (25).
In vitro inhibitor studies.
Inhibitor
screening was performed using the standard assay (50 µM
4-NH2-10-CH3-Pteglu5) and ~33
µunits of GGH/assay tube. Agents were tested at several
concentrations of
1 mM when solubility permitted. More
formal inhibition analyses were undertaken for the glutamine
antagonists using at least seven concentrations of each compound and a
30-min preincubation of inhibitor with enzyme before commencing the
assay by adding substrate. Ki
app values were obtained by fitting (25) to data the
following equation: Inhibited Velocity = Vmax/{1 + ([I]/Ki app)}.
Analysis of polyglutamate chain formation. HT-1080 cells (2-5 × 107) were incubated in complete medium containing 10 µM [3H]MTX at 37° for 24 hr or as described in text and figure legends. After the specified treatments, cells were harvested and suspended in 500 µl of boiling 50 µM Na phosphate, pH 5.5, and then placed in a boiling water bath for 5 min. Extracts were centrifuged at 20,000 × g for 10 min, and supernatants were analyzed by HPLC as previously described (26).
| |
Results and Discussion |
|---|
|
|
|---|
Activity and secretion of GGH from cultured cell lines.
In all
instances, the HPLC profile of GGH reaction products for assays
(4-NH2-10-CH3-Pteglu5 as substrate)
was consistent with an exopeptidase mode of action (Fig.
1A). This mode of activity is characterized by
successive and sequential cleavage of end
-glutamyl residues, with
cleavage stopping at the one remaining glu residue (i.e.,
4-NH4-10-CH3-Pteglu1 when standard
substrate is used). We (28) and, more recently, others (29) have
reported this activity for human GGH from cultured cell lines, although the possibility that other activity forms exist for other human cell
types or tissues (e.g., tissues involved in absorptive processes) cannot be ruled out at this stage. In this study, a strict exopeptidase mode of action was also found for HT-1080 GGH at various levels of
purity and for other poly-
-glutamate substrates [i.e.,
Pteglu4 and pABglu5 (vida infra)].
This clearly contrasts with data obtained from studies of many rodent
tissues and rodent cultured cell lines. For these species, the enzyme
has displayed either a mixed or an endopeptidase mode of cleavage for
folate and antifolate poly-
-glutamates (11, 19). Human GGH is
therefore distinct from rodent GGH in this respect.
|
-hexosamidase, a lysosomal marker enzyme (23),
was also secreted in parallel with HT-1080 GGH, supporting the
contention that secreted GGH came from the lysosomal compartment (data
not shown). Conversely, the activities of cytosolic enzymes,
glyceraldehyde-3-phosphate dehydrogenase, and dihydrofolate reductase
in the media remained low (or below detection for the latter)
throughout the duration of growth for both control and
NH4Cl-treated cells. Secreted HT-1080 GGH also displayed an
exopeptidase mode of activity on assay.
Purification of GGH from HT-1080 cells. GGH bound avidly to an agarose-immobilized dye matrix (Reactive Green 5) at pH 7.5 and could be eluted as a sharp band of activity by application of a salt gradient. Multiple protein components were detected on SDS-PAGE analysis of the eluted fractions with highest specific activity, nevertheless, this proved to be an ideal first step in the purification of GGH with good yield (51-82%, n = 4) and substantial purification (110-386-fold, n = 4). Further purification of HT-1080 GGH was achieved by passage on a organomercurial column (thiol elution) and Sephacryl-200 chromatography as summarized in Table 1. For both of these steps, activity behaved homogeneously (i.e., eluted as a single peak); however, omission of thiols from the S-200 equilibration buffer (in initial runs) resulted in an extremely broadly eluting activity peak. In addition, total activity recovered from the gel filtration step (see Table 1), and stability of the resulting preparation was low even when thiols and Zn2+ were present.
|
1500-fold from crude extract) unless
otherwise stated.
Properties of HT-1080 GGH.
Concentrated partially pure GGH was
stable at
75° for a 6-month period and demonstrated only ~6%
activity loss after five freeze (
196°)/thaw (37°) cycles. Several
general properties in relation to GGH activity were noted. (a) Activity
was highly pH dependent with an acidic optimum in the range of 4- 6.5 (Fig. 2A). This is a similar finding to that reported
for murine and bovine species of GGH (12, 19) and consistent with its
assumed lysosomal localization. (b) Although activity was routinely
assayed with buffer containing ZnCl2 and DTT, omission of
DTT often diminished activity by 1-15%. In no instance did omission
of ZnCl2 result in lower activity, even with the purist
preparations and after exhaustive dialysis. When activation by DTT (2 mM) was apparent, an equal extent of activity enhancement
could be obtained with
-mercaptoethanol or cysteine but not cystine
or glutathione (data not presented). When the MTEN buffering component
was replaced by citrate, succinic, and
2-(N-morpholino)ethanesulfonic acid buffers, each at 50 mM, pH 4.5, and also containing DTT and ZnCl2, identical catalytic rates were observed. (c) GGH was inhibited by
anions or polyanions as previously noted for other species of enzyme
(2), presumably by binding a putative polyglutamate anion receptor site
on the enzyme (18). Activity was completely abolished by 2 mM and 1 mM Na acetate at pH 4.5 and 5.5, respectively.
|
Physicochemical properties.
The molecular mass of native
HT-1080 GGH was estimated on four occasions by gel filtration
chromatography on Sephacryl S-200 in the presence of 2 mM
-mercaptoethanol and 1 mM DTT. Values of apparent
molecular mass obtained by interpolation of the calibration plot (Fig.
2B) ranged from 81.0 to 93.9 kDa; the average was 83.0 ± 9.6 kDa
(±1 standard deviation). Omission of thiols from buffer resulted in a
spreading of activity elution on initial trials, a phenomenon that did
not seem to be related to the purity of material analyzed. This
molecular mass estimate for HT-1080 GGH differs considerably from those
reported for the partially pure jejunal enzyme [75 kDa, (10)], bovine
liver GGH [108 kDa, (12)], and the secreted rat hepatoma enzyme [120
kDa, (19)]; each determined by gel filtration methodologies. For the
latter enzyme species, more recent studies (8) with pure preparations
(without deglycosylation) indicated a diffuse band of 55 kDa on
SDS-polyacrylamide gel electrophoresis analysis, which is suggestive of
quaternary structure for at least this rodent GGH species. Quaternary
structure, extent of glycosylation, and how these factors contribute to
differing apparent molecular mass estimates for various eukaryotic
sources of GGH have yet to be determined.
Enzyme kinetic parameters and substrate specificity.
The
catalytic activity of HT-1080 GGH was measured with varied
concentrations of Pteglu2,
4-NH2-10-CH3-Pteglu2,
pABglu2, and the corresponding glu5
derivatives. The amount of enzyme and the time points selected in
assays were chosen to avoid substantial substrate depletion and to
permit the generation of predominantly glu4 product
derivatives only in the case of glu5 substrates. All
substrates conformed to Michaelis kinetics, yielding rectangular hyperbolic curves when reaction velocities were plotted against substrate concentration. Iterative fitting of the Michaelis-Menten equation to data enabled estimation of Km and
Vmax parameters, as listed in Table
2. Most notably, the enzyme showed preference toward the
longer-chain derivatives with 15-42-fold lower
Km values for the
glu5 versus glu2 forms for each of the
substrate types analyzed. A similar observation of distinct preference
for the longer-chain
-glutamate substrates has been noted in other
studies (some are reviewed in Ref. 2), including the early work with partially pure human liver enzyme [although only in a qualitative fashion (18)] and more recent work by Sirotnak et al. (11) with murine GGH. In the latter study, analyses of GGH activity in crude
preparations of L1210 and mouse small intestine revealed respective 3- and 7.7-fold decreases in Km values
for the glu4 derivatives of
4-NH2-10-CH3-Pte versus the glu2
derivative (11). It is also worthy of note that in this same study
(11), enriched GGH from mouse sarcoma 180 cells and mouse intestine
extract (through ammonium sulfate fractionation) displayed
Km values of 19.7 and 86.4 µM, respectively, for
4-NH2-10-CH3-Pteglu2. These
values encompass the value obtained in the current study with human
enzyme using identical substrate (52.6 µM; Table 2).
|
-glutamate substrate, where the
Km value for pABglu5
was only 1.6-fold higher than that for Pteglu5 (Table 2).
The partially pure human liver GGH was also found to have qualitatively
good activity with either Pteglu4 or
-glu4
as substrate (18, 32). Combined, these data strongly argue against the existence of a Pte-specific binding site on the surface of human GGH,
although it is interesting to note that the
4-NH3-10-CH2-Pte modification of
Pteglu2 and Pteglu5 resulted in a 3.2- and
3.8-fold reduction in affinity, respectively (Table 2). Also of
significance is the fact that the maximal possible catalytic activity
for each substrate examined (i.e., Vmax; Table
2) is approximately equal , so differences in overall catalytic
efficiency for substrates are primarily due to binding considerations.
The properties of substrate specificity for HT-1080 reported here seem
to reflect a general consensus of properties for all eukaryotic species
of GGH, regardless of the mode of reaction (endo- or exo-) catalyzed.
One exception to this may be the chicken intestine enzyme, which was
reported to be active toward Pteglu5 but not
Pteglu3,
-glu5, or
N-trinitrobenzoyl-
-glu5 (2, 33). Interestingly, the dipeptide analog of the quinazoline antifolate ICI
198583 (2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic
acid), which has a D-enantiomeric glutamic acid residue
appended at the
-position of the folyl L-glutamate
[i.e., ICI 198583-
-D-glu (34)], did not serve as a
substrate (data not presented), indicating binding stereoselectivity for the human GGH active site.
Inhibition of HT-1080 GGH.
2-Mercaptomethylglutaric acid was
reported to be inhibitory toward partially pure chicken pancreas GGH
but not lysosomal hog kidney GGH (17, 35). Experiments performed in the
current study with HT-1080 GGH failed to show any in vitro
inhibition of activity by this agent at
250 µM, at
least at pH 4.5. To identify inhibitors, we used initially the
quantitative HPLC assay and later the high through-put capillary
electrophoresis assay to screen a series of potential inhibitor
compounds selected on the basis of structural considerations. Many of
these compounds were folate or antifolate derivatives with unusual
glutamate modifications or substitutions, although none selected
displayed significant inhibition,1
including ICI 198583-
-D-glu. However, the "glutamine
antagonists azaserine, acivicin, and DON, all of which are
well-characterized inhibitors of
-glutamyltranspeptidase [EC
3.3.2.2 (36)], were found to be inhibitory toward the human GGH.
Without regard to the mode of inhibition, or the presence of substrate,
and using inhibition reaction rates after a 30-min preincubation with
enzyme, respective Ki
app values of 5.7, 0.85, and 0.05 mM were derived for these agents (Fig. 3A).
|
-glutamyltranspeptidase, an enzyme that catalyzes the transfer of
the
-glutamyl of glutathione and other
-glutamyl compounds to a
number of acceptors (36). The rationale for testing these antagonists
against GGH was therefore based on the possibility of similar active
site architecture for the two enzymes because both catalyze the
cleavage of a
-glutamyl moiety. It has also been established that
each of these compounds binds irreversibly to the
-glutamyltranspeptidase active site, and although formal experiments
have not been undertaken to determine whether covalent modification
also occurs for GGH, it is interesting to note that time dependency for
DON inhibition is observed (Fig. 3B), a phenomenon that is frequently
observed for irreversible enzyme inhibitors.
Cell culture studies of GGH inhibition by DON and its effect on MTX
action.
The cytotoxicity of DON toward the HT-1080 line by DON
alone was determined before assessing the potential of this agent to enhance MTX retention and action. Cell survival after a 24-hr exposure
to DON at concentrations of
500 µM was measured using the
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide cytotoxicity assay. For the HT-1080 cell line, < ~5% cell
death was observed at 10 µM DON, so this was the maximal concentration adopted in subsequent studies.
glu3) was higher for each of the cell lines
when DON was also present (1.8- and 3.3-fold higher for HT-1080 and
HS-16, respectively). Such altered polyglutamylation profiles are
consistent with GGH inhibition.
|
|
-glutamyltranspeptidase [as mentioned previously, (36)]
and several glutamine dependent amido transferases involved in
nucleotide biosynthesis (37). Thus, other cellular perturbations besides those resulting from GGH inhibition are possibly occurring, and
this factor must warrant consideration when interpreting data presented
in Tables 3 and 4.
Concluding comments. The properties of purified human GGH reported in the current study have similarities to the few characteristics noted for human liver GGH but differ in several respects to those reported for rodent, bovine liver, and human jejunal and brush border enzymes. GGH for cultured human cell lines (excluding those derived from tissues with absorptive functions) may be predominantly one species, an exopeptidase that is highly sequestered into the lysosome. The only indication of possible GGH variants identified in the current work could also be explained on the basis of variable post-translational modification of the enzyme (i.e., glycosylation).
Consideration for the potential of GGH inhibition as a therapeutic strategy in conjunction with antifolate exposure has been previously described (17). Some additional support for this strategy comes from reports of several eukaryotic cell lines with increased GGH activity that are resistant to MTX and/or other antifolate drugs (28, 38, 39) and the current view that the majority of patients with acute myelogenous leukemia are intrinsically resistant to MTX due to impaired polyglutamylation (and therefore retention) of the drug (27, 40). The results presented here provide some preliminary detail on the physicochemical and catalytic properties of this candidate target. DON and acivicin may serve as useful lead compounds in the development of specific GGH inhibitors. Furthermore, such agents should prove useful in exploring the relationship between GGH activity levels and antifolate resistance observed in experimental systems and in the clinic. While this article was being reviewed for publication, Yao et al. (41) published the sequence and in vitro expression of human GGH. The cDNA encodes for a polypeptide of ~36 kDa with four consensus asparagine glycosylation sites. Their preliminary characterization studies of expressed protein (including substrate preference) is consistent with those reported here for native enzyme.| |
Footnotes |
|---|
Received October 21, 1996; Accepted January 21, 1997
1 A list of screened compounds and activities is available from the authors on request.
This work was supported by United States Public Health Service Grant CA08010. J.R.B. is an American Cancer Society Professor.
Send reprint requests to: Dr. J. R. Bertino, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 78, New York, NY 10021. E-mail: j-bertino{at}mskcc.org
| |
Abbreviations |
|---|
GGH,
-glutamyl hydrolase;
Pte, pteroyl;
HPLC, high performance liquid chromatography;
MTX, methotrexate;
pAB, para-aminobenzoyl;
DTT, dithiothreitol;
DON, 6-diazo-5-oxo-L-norleucine;
glun,
-linkage of successive L-glutamyl
residues, where n is number of residues.
| |
References |
|---|
|
|
|---|
| 1. | Allegra, C. J. Antifolates, in Cancer Chemotherapy, Principles, and Practice (B. A. Chabner and I. M. Collins, eds.). J. B. Lippincott, Philadelphia, 110-153 (1990). |
| 2. | McGuire, J. J. and J. K. Coward. Pteroylpolyglutamates: biosynthesis degradation and function, in Folates and Pterins (R. L. Blakley and S. J. Benkovic, eds.). Wiley Interscience, New York, 135-190 (1990). |
| 3. | Bertino, J. R. Karnofsky Memorial Lecture: ode to methotrexate. J. Clin. Oncol. 11:5-14 (1993)[Medline]. |
| 4. |
Barrueco, J. R. and
F. M. Sirotnak.
Evidence for the facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 Cells.
J. Biol. Chem.
266:11732-11737 (1991) |
| 5. | Garrow, T. A. and B. Shane. Purification and general properties of human folylpolyglutamate synthetase. Adv. Exp. Med. Biol. 338:659-662 (1993)[Medline]. |
| 6. |
Garrow, T. A.,
A. Admon, and
B. Shane.
Expression cloning of a human cDNA encoding folylpoly ( -glutamate) synthetase and determination of its primary structure.
Proc. Natl. Acad. Sci. USA
89:9151-9155 (1992) |
| 7. |
Roy, K.,
K. Mitsugi,
S. Sirlin,
B. Shane, and
F. M. Sirotnak.
Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription.
J. Biol. Chem.
270:26918-26922 (1995) |
| 8. |
Yao, R.,
Z. Nimec,
T. J. Ryan, and
J. Galivan.
Identification, cloning, and sequencing of a cDNA coding for rat -glutamyl hydrolase.
J. Biol. Chem.
271:8525-8528 (1996) |
| 9. | Priest, D. G., C. D. Veronee, M. Mangum, J. M. Bednarek, and M. T. Doig. Comparison of folylpolyglutamate hydrolases of mouse liver, kidney, muscle and brain. Mol. Cell. Biochem. 43:81-87 (1982)[Medline]. |
| 10. |
Wang, T. Y.,
C. J. Chandler, and
C. H. Halsted.
Intercellular pteroylpolyglutamate hydrolase from human jejunal mucosa: isolation and characterization.
J. Biol. Chem.
261:13551-13555 (1986) |
| 11. |
Samuels, L. L.,
L. J. Goutas,
D. G. Priest,
J. R. Piper, and
F. M. Sirotnak.
Hydrolytic cleavage of methotrexate -polyglutamates by folylpolyglutamyl hydrolase derived from various tumors and normal tissues of the mouse.
Cancer Res.
46:2230-2235 (1986) |
| 12. |
Silink, M.,
R. Reddel,
M. Bethel, and
P. B. Rowe.
-Glutamyl hydrolase (conjugase) purification and properties of the bovine hepatic enzyme.
J. Biol. Chem.
250:5982-5994 (1975) |
| 13. |
Elsenhans, B.,
O. Ahmad, and
I. Rosenberg.
Isolation and characterization of pteroylpolyglutamate hydrolase from rat intestinal mucosa.
J. Biol. Chem.
259:6364-6368 (1984) |
| 14. |
Chandler, C. J.,
T. T. Y. Wang, and
C. H. Halsted.
Pteroylpolyglutamate hydrolase from human jejunal brush borders: purification and characterization.
J. Biol. Chem.
261:928-933 (1986) |
| 15. | Silink, M. and P. B. Rowe. The location of glutamate carboxypeptidase in rat liver lysosomes. Biochim. Biophys. Acta 381:28-36 (1975)[Medline]. |
| 16. |
Galivan, J.,
T. Johnson,
M. Rhee,
J. McGuire,
D. Priest, and
V. Vesevan.
The role of folylpolyglutamate synthetase and -glutamylhydrolase in altering cellular folyl- and antifolylpolyglutamates.
Adv. Enzyme Regul.
26:147-155 (1987)[Medline].
|
| 17. | Kalman, T. J. Polyglutamylation of folates and antifolates as a target of chemotherapy, in Pharmacology and Therapeutics: Molecular Aspects of Chemotherapy (E. Borowski and D. Shugar, eds.). Plenum Press, New York, 139-297 (1990). |
| 18. | Baugh, C. M. and C. L. Krumdieck. Naturally occurring folates. Ann. N. Y. Acad. Sci. 186:7-28 (1971)[Medline]. |
| 19. |
O'Connor, B.,
R. Rotundo,
Z. Nimec,
J. McGuire, and
J. Galivan.
Secretion of -glutamyl hydrolase in vitro.
Cancer Res.
51:3874-3881 (1991) |
| 20. |
Goker, E.,
M. Waltham,
A. Kheradpour,
T. Trippett,
M. Mazumdar,
Y. Elisseyeff,
B. Schnieders,
P. Steinherz,
C. Tan,
E. Berman, and
J. R. Bertino.
Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutation.
Blood
86:677-684 (1995) |
| 21. |
Scudiero, D. A.,
R. H. Shoemaker,
K. D. Paull,
A. Monks,
S. Tierney,
T. H. Nofziger,
M. J. Currens,
D. Seniff, and
M. R. Boyd.
Evaluation of a soluble tetrazolium/formazin assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.
Cancer Res.
48:4827-4833 (1988) |
| 22. | Ellis, K. J. and J. F. Morrison. Buffers of constant Ionic strength for studying pH-dependent processes. Methods Enzymol. 87:405-426 (1982)[Medline]. |
| 23. | Waltham, M. C., S. Lin, W.-W. Li, E. Goker, H. Gritsman, W. P. Tong, and J. R. Bertino. Capillary electrophoresis of methotrexate
polyglutamates and its application in evaluation of -glutamyl
hydrolase activity. J. Chromatogr., in press.
|
| 24. | Hall, C. W., I. Liebaers, P. Di Natale, and E. F. Neufeld. Enzymic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol. 50:439-456 (1978)[Medline]. |
| 25. | Duggleby, R. G. Regression analysis of nonlinear arrhenius plot: an empirical model and a computer program. Comput. Biol. Med. 14:447-455 (1984)[Medline]. |
| 26. | Lin, J. T., W. P. Tong, T. M. Trippett, D. Niedzwiecki, Y. Tao, C. Tan, P. Steinherz, B. I. Schweitzer, and J. R. Bertino. Basis for natural resistance to methotrexate in human acute non-lymphoblastic leukemia. Leuk. Res. 15:1191-1196 (1991)[Medline]. |
| 27. | Deleted in proof.Deleted in proof. |
| 28. |
Li, W. W.,
M. Waltham,
W. Tong,
B. I. Schweitzer, and
J. R. Bertino.
Increased activity of -glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX).
Adv. Exp. Med. Biol.
388:536-638 (1993).
|
| 29. |
Rhee, M. S.,
T. J. Ryan, and
J. H. Galivan.
-Glutamyl hydrolase from human tumor cell lines.
Cell. Pharmacol.
2:289-292 (1995).
|
| 30. |
Gonzalez-Noriega, A.,
J. Grubb,
V. Talkad, and
W. Sly.
Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal secretion by impairing receptor recycling.
J. Cell. Biol.
85:839-852 (1980) |
| 31. |
Hasilik, A. and
E. F. Nenfeld.
Biosynthesis of lysosomal enzymes in fibroblasts.
J. Biol. Chem.
255:4937-4945 (1980) |
| 32. |
Baugh, C.,
J. Stevens, and
C. Krumdieck.
Studies on -glutamyl carboxypeptidase.
Biochem. Biophys. Acta
212:116-125 (1970)[Medline].
|
| 33. |
Saini, P. and
I. Rosenberg.
Isolation of pteroyl- -oligoglutamyl endopeptidase from chicken intestine with the aid of affinity chromatography.
J. Biol. Chem.
249:5131-5134 (1974) |
| 34. | Bavetsias, V., A. L. Jackman, R. Kimbell, W. Gibson, F. T. Boyle, and G. M. F. Bisset. Quinazoline antifolate thymidylate synthase inhibitors: gamma-linked L-D, D-D, and D-L dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). J. Med. Chem. 39:73-85 (1996)[Medline]. |
| 35. | Kalman, T. I., V. K. Nayak, and A. R. V. Reddy. Selective inhibition of bacterial carboxypeptidase G and pancreatic conjugase by 2-mercaptomethylglutaric acid, in Chemistry and Biology of Pteridines (B. A. Cooper and V. M. Whitehead, eds.). W. de Gruyter, Berlin, 583-586 (1986). |
| 36. | Meister, A. Metabolism and function of glutathione, in Glutathione: Chemical, Biochemical and Medical Aspects: Part A (D. Dolphin, R. Poulson and O. Avramovic, eds.). John Wiley & Sons, New York, 367-474 (1989). |
| 37. |
Lyons, S. D.,
M. E. Sant, and
R. I. Christopherson.
Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia.
J. Biol. Chem.
265:11377-11381 (1990) |
| 38. |
Rhee, M. S.,
Y. Wang,
M. G. Nair, and
J. Galivan.
Acquisition of resistance to antifolates caused by enhanced -glutamyl hydrolase activity.
Cancer Res.
53:2227-2230 (1993) |
| 39. |
Pizzorno, G.,
B. A. Moroson,
A. R. Cashmore,
O. Russello,
J. R. Mayer,
J. Gallivan,
M. A. Bunni,
D. G. Priest, and
G. P. Beardsley.
Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Cancer Res.
55:566-573 (1995) |
| 40. |
Whitehead, V. M.,
D. S. Rosenblatt,
M. J. Vuchich,
J. J. Shuster,
A. Witte, and
D. Beaulieu.
Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis.
Blood
76:44-49 (1990) |
| 41. |
Yao, R.,
E. Schneider,
T. J. Ryan, and
J. Galivan.
Human -glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro.
Proc. Natl. Acad. Sci. USA
93:10134-10138 (1996) |
This article has been cited by other articles:
![]() |
H. Li, T. J. Ryan, K. J. Chave, and P. Van Roey Three-dimensional Structure of Human gamma -Glutamyl Hydrolase. A CLASS I GLUTAMINE AMIDOTRANSFERASE ADAPTED FOR A COMPLEX SUBSTRATE J. Biol. Chem., June 28, 2002; 277(27): 24522 - 24529. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Cole, B. A. Kamen, R. Gorlick, D. Banerjee, A. K. Smith, E. Magill, and J. R. Bertino Effects of Overexpression of {{gamma}}-Glutamyl Hydrolase on Methotrexate Metabolism and Resistance Cancer Res., June 1, 2001; 61(11): 4599 - 4604. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Rots, R. Pieters, G. J. Peters, P. Noordhuis, C. H. van Zantwijk, G. J.L. Kaspers, K. Hahlen, U. Creutzig, A. J.P. Veerman, and G. Jansen Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia Blood, March 1, 1999; 93(5): 1677 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Rhee, B. Lindau-Shepard, K. J. Chave, J. Galivan, and T. J. Ryan Characterization of Human Cellular gamma -Glutamyl Hydrolase Mol. Pharmacol., June 1, 1998; 53(6): 1040 - 1046. [Abstract] [Full Text] |
||||
![]() |
K. J. Chave, I. E. Auger, J. Galivan, and T. J. Ryan Molecular Modeling and Site-directed Mutagenesis Define the Catalytic Motif in Human gamma -Glutamyl Hydrolase J. Biol. Chem., December 15, 2000; 275(51): 40365 - 40370. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||